After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.
Clovis Oncology (CLVS) stock is dipping on Wednesday as an FDA advisory committee voted against approving the company's lung cancer drug rociletinib yesterday.
An FDA advisory committee delivers a brutal beatdown of Clovis' lung cancer drug rociletinib. It could cost Clovis' CEO his job.
Clovis Oncology (CLVS) stock is continuing to slide on Monday after the FDA questioned its lung cancer drug Friday. An advisory panel is slated to vote on the drug tomorrow.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.